COMPOSITIONS AND METHODS FOR ENHANCING ANALGESIC POTENCY OF COVALENTLY BOUND-COMPOUNDS, ATTENUATING ITS ADVERSE SIDE EFFECTS, AND PREVENTING THEIR ABUSE

• US 20100144645A1
• Filed: 04/16/2007
• Published: 06/10/2010
• Est. Priority Date: 04/14/2006
• Status: Abandoned Application

• Current Assignee: Shire LLC (Shire plc)
• Original Assignee: Shire LLC (Shire plc)
• Inventors: Kirk, Randal J., Krishnan, Suma, Moncrief, James Scott
• Application Number:
  US12/296,715
• Publication Number:
  US 20100144645A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 47/64 Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent peptidic linkers A61K47/65
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/36 Opioid-abuse

Abstract

The invention generally relates to compositions and methods with covalently bound compounds, such as controlled substances covalently attached to a chemical moiety, and opioid antagonists or covalently bound opioid antagonists to enhance analgesic potency and/or attenuate one or more adverse effects of covalently bound compounds, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence), physical dependence or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of a covalently bound compound and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of a covalently bound compound. The methods of the invention comprise administering to a subject an analgesic or sub-analgesic amount of a covalently bound compound and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of a covalently bound compound and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of covalently bound compound. The invention also relates to the addition of covalently-bound opioid antagonists to the compositions containing covalently bound compounds such that if the compositions are subjected to manipulation by illicit chemists, the opioid antagonist is released effectively reducing or eliminating the euphoric effect of the covalently bound compounds.

Claims

1. A composition for oral administration comprising (1) an analgesic or sub-analgesic amount of an opioid agonist conjugate comprising an opioid agonist covalently bound to an amino acid or peptide, and (2) an effective amount of an opioid antagonist conjugate to reduce the euphoric effect of the opioid agonist conjugate, wherein the opioid antagonist conjugate is an opioid antagonist covalently bound to an amino acid or peptide.

2. The composition of claim 1, wherein the opioid agonist is a bimodally-acting opioid agonist.

3. The composition of claim 1, wherein the composition comprises an amount of the opioid antagonist conjugate effective to enhance the analgesic potency of the covalently bound opioid agonist conjugate and to enhance the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of the covalently bound opioid agonist conjugate.

5. The composition of claim 1, wherein the opioid antagonist is naltrexone, naloxone, or nalmefene.

8. The composition of claim 1, wherein the opioid agonist is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, barbiturates, benzodiazepines, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl, hydrocodone, hydromorphone, hydromorphodone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meprobamate, meptazinol, metazocine, methadone, methyldihydromorphinone, metopon, methylphenidate, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papavereturn, paregoric, pemoline, pentazocine, phenadoxone, phendimetrazine, phendimetrazone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, propylhexedrine, sufentanil, sufentanyl, tilidine, and tramadol.

9. The composition of claim 2, wherein the bimodally-acting opioid agonist is selected from the group consisting of morphine, codeine, pentazocine, buprenorphine, methadone, enkephalin, dynorphin and endorphin.

12. The composition of claim 1, wherein the opioid agonist conjugate is an opioid agonist covalently attached to a single amino acid.

13. The composition of claim 12, wherein the single amino acid is selected from serine, glutamic acid, glycine, proline, phenylalanine, leucine, isoleucine and alpha aminoisobutyric acid.

14. The composition of claim 1, wherein the opioid agonist conjugate is an opioid agonist covalently attached to a dipeptide, tripeptide, tetrapeptide, hexapeptide, heptapeptide or pentapeptide.

15. The composition of claim 14 wherein the dipeptide is alanine-proline, pyroglutamic acid-glutamic acid or glutamic acid-glutamic acid.

17. The composition of claim 14, wherein the tripeptide is Gly-Gly-Leu, Gly-Gly-Glu, Gly-Gly-Ile, Gly-Gly-Phe, Gly-Gly-alpha aminoisobutyric acid, Gly-Leu-Ile, Gly-Phe-Ile, Gly-Leu-Leu, Gly-Phe-Leu, Leu-Pro-Glu, Leu-Pro-Leu, Leu-Pro-Phe, Pro-Pro-Glu, Pro-Pro-Leu, Pro-Pro-Ile, Pro-Pro-Phe, Glu-Glu-Glu, Leu-Leu-Glu, Leu-Leu-Leu, Glu-Pro-Val, Glu-Tyr-Val or Ile-Tyr-Val.

20. The composition of claim 14, wherein the pentapeptide is Glu₅, Gly₄-Leu, Gly₄-Ile, Gly₄-Aib, Gly₄-Phe, Gly₂-Glu₃, Glu₃-Gly₂-Aib, Glu₂-Gly₂-Leu, Glu₂-Gly₂-Ile or Tyr-Tyr-Phe-Phe-Ile.

21. The composition of claim 1, wherein the opioid agonist conjugate is an opioid agonist covalently bound to a single amino acid or peptide selected from Lys, Ser, Ala, Phe, Ile, Pro-Pro-Leu, Pro-Pro-Ile, Val-Val, Lys-Lys, Gly-Gly-Ile, Phe-Phe-Ile, Phe-Phe-Leu, Thr-Thr-Val, Tyr-Tyr-Val, Tyr-Tyr-Phe, Glu-Glu-Val, Asp-Asp-Val, Lys-Lys-Val, Glu-Glu-Phe-Phe-Ile, Glu-Glu-Phe-Phe-Phe, Tyr-Tyr-Ile, Asp-Asp-Ile, Tyr-Tyr-Phe-Phe-Ile, Tyr-Tyr-Lys-Tyr-Tyr, Phe-Phe-Lys-Phe-Phe, (Lys-Lys-Gly-Gly) and [(1)-Lys-(d)-Lys-Leu]₂.

22. A method for preventing the abuse potential of an opioid composition comprising oral administrating to a patient a composition of claim 1.

23. A method for treating pain in a human subject comprising oral administrating to a patient a composition of claim 1.

28. The composition of claim 1, wherein the opioid agonist targets a GPCR.

4. (canceled)

6-7. -7. (canceled)

10-11. -11. (canceled)

16. (canceled)

18-19. -19. (canceled)

24. A composition comprising (1) an analgesic or sub-analgesic amount of a G-protein coupled receptor (GPCR) agonist conjugate comprising a GPCR agonist covalently bound to an amino acid or peptide, wherein the GPCR agonist conjugate does not promote endocytosis and resensitization of the targeted GPCR and (2) an effective amount of an opioid agonist conjugate comprising a mu opioid receptor agonist covalently bound to an amino acid or peptide, wherein the mu opioid receptor agonist promotes the endocytosis of the GPCR.

25. The composition of claim 24, wherein the mu opioid receptor agonist is methadone, fentanyl, sulfentanil, remi-fentanyl, etonitazene, or etorphine.

26. A composition comprising (1) an analgesic or sub-analgesic amount of an opioid agonist conjugate comprising an opioid agonist that targets a G-protein coupled receptor (GPCR) covalently bound to a single amino acid or peptide and (2) racemic methadone, wherein the opioid agonist does not promote endocytosis and resensitization of the targeted GPCR and the methadone reduces or prevents constipation.

27. The composition of claim 26, wherein the opioid agonist is morphine.

30. The composition of claim 26, wherein A the racemic methadone is covalently bound to a single amino acid or peptide.

32. The compound of claim 30, further comprising an amount of an opioid antagonist conjugate sufficient to prevent the euphoric effect of the covalently bound opioid agonist and said methadone, wherein the opioid antagonist conjugate is an opioid antagonist is covalently bound to a single amino acid or peptide.

29. (canceled)

31. A composition comprising (1) an analgesic or sub-analgesic amount of an agonist conjugate comprising an agonist that targets a G-protein coupled receptor (GPCR) covalently bound to a single amino acid or peptide, wherein the agonist does not promote endocytosis and resensitization of the targeted GPCR, (2) a mu opioid receptor agonist conjugate comprising a mu opioid receptor agonist covalently bound to a single amino acid or peptide, and (3) an opioid antagonist compound comprising an opioid antagonist covalently bound to a single amino acid or peptide, wherein the mu opioid receptor agonist compound promotes the endocytosis of the GPCR, the mu opioid receptor agonist compound reduces, prevents or delays the development of tolerance to and/or physical dependence on particular drugs that target GPCRs and the opioid antagonist compound is present in an amount sufficient to prevent the euphoric effect of the covalently bound agonist and the covalently bound mu opioid receptor agonist.

33. (canceled)